US · RCEL
AVITA Medical, Inc.
- Sector
- Healthcare · Medical - Devices
- Headquarters
- Valencia, CA 91355
- Website
- avitamedical.com
Price · as of 2025-12-31
$4.44
Market cap 124.96M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $29.49 | +564.19% |
| Intrinsic Value(DCF) | $2.11 | -52.48% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $3.56 | $0.00 | |||
| 2012 | $0.00 | $0.00 | |||
| 2013 | $0.00 | $19.32 | |||
| 2014 | $0.00 | $0.00 | |||
| 2015 | $0.00 | $116.57 | |||
| 2016 | $0.00 | $0.00 | |||
| 2017 | $0.00 | $0.00 | |||
| 2018 | $0.00 | $0.00 | |||
| 2019 | $0.00 | $0.00 | |||
| 2020 | $0.00 | $0.00 | |||
| 2021 | $0.00 | $0.00 | |||
| 2022 | $13.29 | $27.97 | $371.73 | $0.00 | $0.00 |
| 2023 | $17.13 | $30.15 | $70.58 | $0.00 | $0.00 |
| 2024 | $8.30 | $22.39 | $4.06 | $0.00 | $0.00 |
| 2025 | $5.27 | $29.49 | $0.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates AVITA Medical, Inc.'s (RCEL) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $29.49
- Current price
- $4.44
- AI upside
- +564.19%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$2.11
-52.48% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| RCEL | AVITA Medical, Inc. | $4.44 | 124.96M | +564% | -52% | — | — | -3.02 | -8.82 | 2.05 | -3.30 | — | -6.59 | 82.13% | -58.56% | -67.85% | 799.72% | 463.33% | -71.40% | -0.13 | -8.38 | 0.57 | 0.44 | 0.20 | -2720.00% | 1145.00% | -4647.00% | -21.25% | -0.50 | 344.68% | 0.00% | 0.00% | 27.27% | -3.12 | -4.19 | 1.83 | -10.70 |
| APYX | Apyx Medical Corporation | $3.27 | 134.17M | +662% | -86% | — | — | -1.69 | 2.80 | 0.83 | -2.79 | -7.60 | 2.80 | 61.04% | -39.18% | -48.78% | -115.17% | -88.10% | -32.70% | 2.73 | -3.19 | 5.26 | 4.40 | -0.42 | 2222.00% | -811.00% | 22461.00% | -47.15% | -1.68 | -87.74% | 0.00% | 0.00% | 0.00% | -2.49 | -2.50 | 0.97 | -0.58 |
| FONR | FONAR Corporation | $18.60 | 114.82M | +450% | -66% | +79% | -33% | 9.23 | 0.57 | 0.94 | 4.97 | — | 0.60 | 81.67% | 11.12% | 7.99% | 6.30% | 5.87% | 4.95% | 0.23 | 452.88 | 8.45 | 8.14 | -1.07 | -1961.00% | 143.00% | -4388.00% | 7.56% | 0.66 | 4.86% | 0.00% | 0.00% | 4.62% | 6.98 | 10.88 | 0.78 | 2.37 |
| HYPR | Hyperfine, Inc. | $1.07 | 81.53M | +2,340% | -64% | — | — | -1.74 | 1.45 | 5.51 | -0.80 | — | 1.45 | 45.70% | -335.33% | -315.90% | -61.03% | -410.39% | -53.19% | 0.01 | — | 6.15 | 5.26 | 0.89 | -968.00% | 1684.00% | -813.00% | -55.17% | -4.44 | -371.71% | 0.00% | 0.00% | 0.00% | -0.78 | -0.86 | 2.61 | -3.97 |
| LUCD | Lucid Diagnostics Inc. | $1.44 | 146.54M | +85,309% | -60% | — | — | -1.54 | 13.02 | 16.16 | -1.56 | — | 15.08 | -90.20% | -1059.64% | -1047.61% | -2956.43% | 5531.77% | -157.04% | 3.94 | -1771.23 | 1.07 | 0.97 | 0.02 | -1667.00% | 7900.00% | 3556.00% | -63.78% | -1.88 | 5379.70% | 0.00% | 0.00% | 0.00% | -1.50 | -1.54 | 15.90 | -12.37 |
| NSPR | InspireMD, Inc. | $1.78 | 75.42M | +1,242% | -35% | — | — | -3.72 | 3.30 | 16.99 | -2.61 | — | 3.30 | 21.49% | -478.00% | -456.63% | -84.68% | -1143.45% | -67.77% | 0.06 | — | 5.28 | 4.80 | 0.50 | -732.00% | 1296.00% | 3887.00% | -19.54% | -2.85 | -794.20% | 0.00% | 0.00% | 7.17% | -2.59 | -3.73 | 12.38 | -2.29 |
| OVID | Ovid Therapeutics Inc. | $1.63 | 116.08M | +1,596% | -87% | — | — | -1.39 | 0.54 | 65.14 | 0.03 | — | 0.54 | 100.00% | -10933.75% | -4670.14% | -33.88% | -444.08% | -22.38% | 0.22 | — | 5.32 | 5.04 | 0.20 | -5000.00% | 4439.00% | 2201.00% | -151.96% | -5.32 | -402.05% | 0.00% | 0.00% | 1.37% | 0.02 | 0.03 | -2.56 | -5.32 |
| QIPT | Quipt Home Medical Corp. | $3.63 | 161.41M | +679% | +41,027% | -84% | — | -9.83 | 0.75 | 0.31 | 5.02 | -17.48 | 183.07 | 70.09% | -1.56% | -3.13% | -8.67% | -2.44% | -3.34% | 0.85 | -0.79 | 1.46 | 0.64 | 2.52 | 5625.00% | 3883.00% | 108.00% | 24.09% | 0.50 | 11.61% | 0.00% | 0.00% | 0.12% | -39.68 | 8.33 | 0.62 | 0.40 |
| STTK | Shattuck Labs, Inc. | $3.92 | 187.78M | +1,035% | -87% | — | — | -0.83 | 0.78 | 10.91 | 0.09 | — | 0.78 | 100.00% | -1408.27% | -1318.13% | -67.23% | -568.84% | -60.18% | 0.04 | — | 8.88 | 8.19 | 0.70 | -2732.00% | 24526.00% | -2580.00% | -97.02% | -6.79 | -427.68% | 0.00% | 0.00% | 0.00% | 0.09 | 0.12 | -1.25 | -4.52 |
| VANI | Vivani Medical, Inc. | $1.23 | 72.67M | — | — | — | — | -2.53 | 3.37 | — | -2.49 | — | 3.37 | 0.00% | — | — | -122.42% | -125.35% | -53.77% | 1.10 | — | 3.41 | 3.11 | -0.04 | -1400.00% | — | -1319.00% | -35.94% | -3.47 | -108.41% | 0.00% | 0.00% | 0.00% | -2.45 | -2.83 | — | -4.16 |
About AVITA Medical, Inc.
AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company has a research collaboration with the University of Colorado School of Medicine to establish pre-clinical proof-of-concept for a spray-on treatment of genetically corrected cells; and a research collaboration with Houston Methodist Research Institute to explore molecular reversal of cellular aging through a novel cell suspension delivery system. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical Inc. in December 2020. AVITA Medical Inc. was incorporated in 2000 and is based in Valencia, California.
- CEO
- Cary G. Vance
- Employees
- 260
- Beta
- 1.80
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($2.11 ÷ $4.44) − 1 = -52.48% (DCF, example).